Literature DB >> 21809146

[Benign focal hepatic lesions].

S Baroud1, N Bastati, H Prosch, W Schima, A Ba-Ssalamah.   

Abstract

A profound knowledge of the various benign focal hepatic lesions and selection of the most suitable radiological examination modality is essential for achieving an accurate characterization of a hepatic lesion and in turn will determine the further patient management. This will avoid unnecessary agitation to both patient and the referring clinician and limits time-consuming, costly and risky biopsies to an absolute minimum. The following article will discuss the typical and atypical appearances of the most frequent and clinically relevant benign focal hepatic lesions with ultrasound, computed tomography and magnetic resonance imaging.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21809146     DOI: 10.1007/s00117-010-2127-1

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  37 in total

1.  Best cases from the AFIP: giant cavernous hemangioma.

Authors:  Prasanth M Prasanna; Scott E Fredericks; Steven S Winn; Robert A Christman
Journal:  Radiographics       Date:  2010 Jul-Aug       Impact factor: 5.333

2.  MR imaging of benign focal liver lesions.

Authors:  Ahmed Ba-Ssalamah; Susanne Baroud; Nina Bastati; Aliya Qayyum
Journal:  Magn Reson Imaging Clin N Am       Date:  2010-08       Impact factor: 2.266

3.  Solitary necrotic nodule of the liver: always benign?

Authors:  Kemal Deniz; Ganime Coban
Journal:  J Gastrointest Surg       Date:  2009-12-09       Impact factor: 3.452

4.  Solitary necrotic nodule of the liver: MR findings in 33 pathologically proved lesions.

Authors:  Li Geng; Chuan Lin; Bin Huang; Xing-An Long; Bing-Hua Dai; Wen-Ming Cong; Jia-Mei Yang
Journal:  Eur J Radiol       Date:  2011-02-26       Impact factor: 3.528

5.  Frequency of benign hepatic lesions incidentally detected with contrast-enhanced thin-section portal venous phase spiral CT.

Authors:  M Völk; M Strotzer; M Lenhart; J Techert; J Seitz; S Feuerbach
Journal:  Acta Radiol       Date:  2001-03       Impact factor: 1.990

6.  Central scars in primary liver tumors: MR features, specificity, and pathologic correlation.

Authors:  E Rummeny; R Weissleder; S Sironi; D D Stark; C C Comptom; P F Hahn; S Saini; J Wittenberg; J T Ferrucci
Journal:  Radiology       Date:  1989-05       Impact factor: 11.105

7.  Confident non-invasive diagnosis of pseudolesions of the liver using diffusion-weighted imaging at 3T MRI.

Authors:  Julia Fruehwald-Pallamar; Nina Bastati-Huber; Negar Fakhrai; Marion Jantsch; Stefan Puchner; Andreas M Herneth; Ahmed Ba-Ssalamah
Journal:  Eur J Radiol       Date:  2011-04-19       Impact factor: 3.528

Review 8.  Management of benign hepatic tumors.

Authors:  Joseph F Buell; Hadrien Tranchart; Robert Cannon; Ibrahim Dagher
Journal:  Surg Clin North Am       Date:  2010-06-08       Impact factor: 2.741

9.  Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience.

Authors:  Paulette Bioulac-Sage; Hervé Laumonier; Gabrielle Couchy; Brigitte Le Bail; Antonio Sa Cunha; Anne Rullier; Christophe Laurent; Jean-Frédéric Blanc; Gaelle Cubel; Hervé Trillaud; Jessica Zucman-Rossi; Charles Balabaud; Jean Saric
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

10.  MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement.

Authors:  Kyongtae T Bae; Cheng Tao; Fang Zhu; James E Bost; Arlene B Chapman; Jared J Grantham; Vicente E Torres; Lisa M Guay-Woodford; Catherine M Meyers; William M Bennett
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-01       Impact factor: 8.237

View more
  2 in total

1.  [Focal nodular hyperplasia and hepatocellular adenoma].

Authors:  N Bastati-Huber; S Pötter-Lang; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-01       Impact factor: 0.635

2.  [Modern diagnostics of cystic liver lesions and hemangiomas].

Authors:  S Pötter-Lang; G Brancatelli; N Bastati-Huber; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-01       Impact factor: 0.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.